Monthly Archives: June 2012
JAK/STAT Pathway: Overview
A discussion with a panel of global key thought leaders regarding Myeloproliferative Neoplasms (MPNs). To learn more about MPNs please visit Exploring MPN at www.exploringmpn.com or MPN Connect at www.mpnconnect.org
A quote for you...
Powered By Optimism Quotes
Myelofibrosis Diagnosis – by Rebecca Lashley
Although this is covered in the introduction to myelofibrosis, I thought this article by Rebecca Lashley was a good summary of myelofibrosis and so have added it here. It is probabely a good article to give to family and friends to give them an idea of what this disorder is… Continue reading
save_Vinod_MYELOFIBROSIS.wmv
what exactly happens at bone marrow registration drives? what it means? MYELOFIBROSIS, bethematch.com www.aadp.org
A quote for you...
Powered By Optimism Quotes
Causes of High White Blood Cell Count
There are several possible causes for a high white blood cell count. This count is high when there are more disease-fighting cells in your body. The technical term for this condition is leukocytosis.
Different medical practices may have different limits by which they define high white blood cell count. A… Continue reading
John C. Byrd, M.D. Joins Tragara Pharmaceuticals Scientific Advisory Board
San Diego, CA (PRWEB) May 30, 2012
Tragara Pharmaceuticals, Inc. today announced that Dr. John C. Byrd, director of the division of hematology at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, has joined their scientific advisory board. A widely… Continue reading
Blood Cancer Research Foundation Changes Name
Chicago, IL (PRWEB) April 4, 2011
The MPD Foundation, a patient-led foundation dedicated to the discovery of treatments and a cure for three rare blood cancers (myelofibrosis, polycythemia vera, and essential thrombocythemia) announces today a new name for the organization, which will now be known as the MPN Research Foundation.… Continue reading
Tragaras TG02 Anti-Tumor Activity is Produced via the Depletion of Anti-apoptotic Proteins Mcl-1 and XIAP
San Diego, California (PRWEB) May 31, 2012
Tragara Pharmaceuticals, Inc. today described the mechanism of action by which its novel oral agent, TG02, has demonstrated anti-tumor activity in both hematological and solid tumors. TG02 is a small molecule that equipotently targets the major signaling pathways involving the key cell cycle… Continue reading
European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes Continuing Medical Education Opportunity
Alpharetta, GA (PRWEB) December 08, 2011
Imedex, LLC would like to present the European Focus on Myeloproliferative Neoplasms and Myelodysplatic Syndromes occurring on 4-5 May 2012 in Lisbon, Portugal. This continuing medical education (CME) will have a target audience of hematologists, oncologists, and other health-care professionals (physicians, physicians-in-training, oncology nurses,… Continue reading
MPN Research Foundation and The Leukemia & Lymphoma Society Partner to Spur Innovation in Fibrosis Research
Chicago and White Plains, New York (PRWEB) January 23, 2012
Applicants for this concept grant program (titled the MF Challenge) will have until April 1, 2012 to submit their proposal for funding in the amount of up to $ 100,000 per grant. The grant review will take place in June… Continue reading
COMFORT II – Why is spleen volume so important? and other questions with Dr. Claire Harrison
A discussion with Dr. Claire Harrison regarding spleen volume, low platelet counts and causes of death from Myelofibrosis (MF), interviewed during the EHA Meeting in June of 2011. (Video 4 of 5). For more information on COMFORT II, go to: www.oncuview.tv For more information on COMFORT I, go to: www.oncuview.tv… Continue reading